None listed
Conditions
Brief summary
This study aims to collect data on the efficacy of clinically prescribed cannabis products from a large-scale cohort to examine the relationships between cannabis treatment and concomitant medication use, pain, symptoms, quality of life, mood and sleep measures in a patient population that includes, but is not limited to, cancer patients. Who is it for? You may be eligible to join this study if you have been prescribed medicinal cannabis through the Special Access Scheme B via Cannvalate and their medical practitioner for any condition including, but not limited to, cancer. If you are under 18 years of age your parents must also consent to your participation in the project. Study details All eligible participants will be emailed a link to an online survey. An automated email will be sent at set intervals (2 weeks, 1 month, 3 months, 6 months, 12 months) from the date of first completion asking patients to complete the survey again. In addition, participants will be asked whether they consent to the investigators accessing their medical records in order to store data in a research database for this and future projects. Participants may choose to participate in one component of the study without the other (e.g. complete survey but not consent to medical records access or vice versa). The survey will take approximately 45 minutes to complete and will be a compilation of the following questions and questionnaires: Demographics, Medical Condition that cannabis is prescribed, dosage, duration and administration of cannabis treatment, general health, pain, symptoms, quality of life, mood and sleep measures. It is hoped that this research will contribute to the knowledge of the safety and efficacy of medicinal cannabis products for different medical conditions.
Interventions
Participants will be patients who have been prescribed medicinal cannabis under the Special Access Scheme B via Cannvalate and their medical practitioner. There are various types of medicinal cannabis available in Australia through this scheme and none will be excluded. The dose, mode and duration of treatment will vary across participants depending on what they have been prescribed. Participants will be asked to provide this information as part of the survey (if they choose to participate in th
Participants will be patients who have been prescribed medicinal cannabis under the Special Access Scheme B via Cannvalate and their medical practitioner. There are various types of medicinal cannabis available in Australia through this scheme and none will be excluded. The dose, mode and duration of treatment will vary across participants depending on what they have been prescribed. Participants will be asked to provide this information as part of the survey (if they choose to participate in that component of the study) and these data will also be collected from medical records (if participants consent to this). Duration of observation will be over 12 months for the survey component of the study: Upon first completion of the survey then at 2 weeks, one month, 3 months, 6 months and 12 months after first completion. For the database/medical records part of the study follow up will be for 5 years or until the participant ceases using medicinal cannabis, whichever is sooner. Note that participants may take part in the survey without consenting to medical records access and vice versa, or can consent to both parts of the study.
Sponsors
Cannvalate (Australia)
Eligibility
Sex/Gender
All
Healthy volunteers
No
Inclusion criteria
Participants will be any patient who has been prescribed medicinal cannabis through the Special Access Scheme B via Cannvalate and their medical practitioner. Participants may be taking cannabis in any dose, form, duration and frequency, and for any condition. Patients of all ages and genders may participate.
Exclusion criteria
The only exclusion criterion is that a person not having been prescribed medicinal cannabis may not participate.
Outcome results
None listed